Merrimack Pharmaceuticals, Inc. s in-depth stock price analysis indicates that the stock price has dropped -47.57% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -31.65% . Looking at the past 52 week period, the stock price is down -41.41% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Merrimack Pharmaceuticals, Inc. has a negative value of -51.25 compared to overall market performance. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has climbed 3.18% in the past week and advanced 0.93% in the last 4 weeks. The company has outperformed the S&P 500 by 2.35% in the past week but underperformed the index by 0.87% in the last 4 weeks.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) : On Friday heightened volatility was witnessed in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) which led to swings in the share price. The stock opened for trading at $3.25 and hit $3.32 on the upside , eventually ending the session at $3.24, with a gain of 0.31% or 0.01 points. The heightened volatility saw the trading volume jump to 1,057,866 shares. The 52-week high of the share price is $9.015 and the company has a market cap of $420 million. The 52-week low of the share price is at $2.83 .
Merrimack Pharmaceuticals Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.04. Analyst had a consensus of $-0.27. The company had revenue of $28.10 million for the quarter, compared to analysts expectations of $28.41 million. The companys revenue was up 71.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.38 EPS.
Company has reported several Insider transactions to the SEC, on Jul 27, 2016, Birgit M. Schoeberl (Head of Discovery) sold 50,000 shares at 5.50 per share price.On Mar 21, 2016, Michael E Porter (director) purchased 5,000 shares at 7.20 per share price.On Mar 1, 2016, William M. Mcclements (Head of Corporate Operations) purchased 2,000 shares at 5.72 per share price.
Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.